The simultaneous analyses of single cell (SC)-, IF-, and IHC-based studies strongly supported that the immunosuppressive function of FSTL3 leads to difficulties in benefiting from immunotherapy in HCC patients. Here, FSTL3 is linked to hepatocellular carcinoma.